Abstract 6109
Background
Brachytherapy unit of the Catalan Institute of Oncology (ICO) is a referral centre on Brachytherapy treatments for Catalonia. A total of 700 treatments are performed per year, mainly in gynaecological, prostate and breast cancer. For the last 5 years, intraoperative brachytherapy has been promoted to be done in other centres, outside in the region. That implies that specialist professionals from our cancer centre go to operating rooms in different hospitals. The surgery process is done outside in the Paediatric hospital and the Brachytherapy treatment is realised in the cancer centre ICO. Aim: to describe nursing activities and roles to facilitate the Brachytherapy treatment done outside and in collaboration with other hospitals.
Methods
Descriptive study on cases done last year 2018 with patients outside ICO, most common type of treatments were sarcoma in paediatric tumours, patients with recurrence disease undergoing salvage after surgery or recurrence for breast cancer. Procedure: When a case arrived to the specialist they confirm indication and initiate the process; On the day of surgery, a medical and nurses team from the brachytherapy unit moves to hospital They perform the placement of internal applicators at the time of surgery. Later next 12-24h patient moves to brachytherapy unit to undergo the protocol of radiation. Once the brachytherapy treatment is finished, patient is discharged. The nursing staff of brachytherapy unit takes charge of plan care during treatment.
Results
Pediatric brachytherapy in oncological patient: experience of collaboration of 5 years with 10 patients treated. A total of 53 breast brachytherapy has been done intraoperative: consolidated collaboration, generates around 3 monthly patients from different medical centers. A total of 10 cases done for salvage brachytherapy in patients with recurrence after surgery.
Conclusions
Intraoperative brachytherapy improves the patient’s accessibility to highly specialized treatments. The procedure and development of this treatment in different hospitals improves results in some tumours, reduces the overall time of treatment. Nursing staff has knowledge and skills for the management and care of this patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract